170 related articles for article (PubMed ID: 37608004)
1. A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.
Quillet JC; Siani-Rose M; McKee R; Goldstein B; Taylor M; Kurek I
Sci Rep; 2023 Aug; 13(1):13022. PubMed ID: 37608004
[TBL] [Abstract][Full Text] [Related]
2. Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.
Siani-Rose M; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
Cannabis Cannabinoid Res; 2023 Feb; 8(1):126-137. PubMed ID: 34874191
[No Abstract] [Full Text] [Related]
3. The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.
Siani-Rose M; McKee R; Cox S; Goldstein B; Abrams D; Taylor M; Kurek I
Cannabis Cannabinoid Res; 2023 Aug; 8(4):642-656. PubMed ID: 35343818
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
5. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
Aran A; Cassuto H; Lubotzky A; Wattad N; Hazan E
J Autism Dev Disord; 2019 Mar; 49(3):1284-1288. PubMed ID: 30382443
[TBL] [Abstract][Full Text] [Related]
7. Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study.
Hacohen M; Stolar OE; Berkovitch M; Elkana O; Kohn E; Hazan A; Heyman E; Sobol Y; Waissengreen D; Gal E; Dinstein I
Transl Psychiatry; 2022 Sep; 12(1):375. PubMed ID: 36085294
[TBL] [Abstract][Full Text] [Related]
8. Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience.
Mostafavi M; Gaitanis J
Semin Pediatr Neurol; 2020 Oct; 35():100833. PubMed ID: 32892960
[TBL] [Abstract][Full Text] [Related]
9. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy.
Bar-Lev Schleider L; Mechoulam R; Saban N; Meiri G; Novack V
Sci Rep; 2019 Jan; 9(1):200. PubMed ID: 30655581
[TBL] [Abstract][Full Text] [Related]
10. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders.
Agarwal R; Burke SL; Maddux M
BMC Psychiatry; 2019 Oct; 19(1):328. PubMed ID: 31664964
[TBL] [Abstract][Full Text] [Related]
11. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
[TBL] [Abstract][Full Text] [Related]
12. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children.
West PR; Amaral DG; Bais P; Smith AM; Egnash LA; Ross ME; Palmer JA; Fontaine BR; Conard KR; Corbett BA; Cezar GG; Donley EL; Burrier RE
PLoS One; 2014; 9(11):e112445. PubMed ID: 25380056
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Silva EAD; Medeiros WMB; Santos JPMD; Sousa JMM; Costa FBD; Pontes KM; Borges TC; Espínola C; Andrade E Silva AH; Nunes ELG; Alves NT; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2024; 46():e20210396. PubMed ID: 35617670
[TBL] [Abstract][Full Text] [Related]
14. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.
Silva EAD; Medeiros WMB; Torro N; Sousa JMM; Almeida IBCM; Costa FBD; Pontes KM; Nunes ELG; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2022 Jun; 44():e20200149. PubMed ID: 34043900
[TBL] [Abstract][Full Text] [Related]
15. Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review.
Fletcher S; Pawliuk C; Ip A; Huh L; Rassekh SR; Oberlander TF; Siden H
Child Care Health Dev; 2022 Jan; 48(1):33-44. PubMed ID: 34403168
[TBL] [Abstract][Full Text] [Related]
16. CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure.
Lambros AM; Sagar KA; Dahlgren MK; Kosereisoglu D; El-Abboud C; Smith RT; Gruber SA
Sci Rep; 2023 Apr; 13(1):5869. PubMed ID: 37041309
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Poleg S; Golubchik P; Offen D; Weizman A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
[TBL] [Abstract][Full Text] [Related]
18. Urinary metabolomics using gas chromatography-mass spectrometry: potential biomarkers for autism spectrum disorder.
Khan ZUN; Chand P; Majid H; Ahmed S; Khan AH; Jamil A; Ejaz S; Wasim A; Khan KA; Jafri L
BMC Neurol; 2022 Mar; 22(1):101. PubMed ID: 35300604
[TBL] [Abstract][Full Text] [Related]
19. Children with Autism Spectrum Disorder Show Impairments During Dynamic Versus Static Grip-force Tracking.
Lidstone DE; Miah FZ; Poston B; Beasley JF; Mostofsky SH; Dufek JS
Autism Res; 2020 Dec; 13(12):2177-2189. PubMed ID: 32830457
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Dispensing and Utilization Patterns of Medical Cannabis Products in State Licensed Cannabis Dispensaries.
Tanco K; Olson A; Fellman B; Jankowski M; Lai SY; Shete S; Harbison K; Scheid J; Bruera E
J Palliat Med; 2023 Nov; 26(11):1482-1487. PubMed ID: 37285183
[No Abstract] [Full Text] [Related]
[Next] [New Search]
